» Articles » PMID: 1703321

Complementation of the Mitotic Activator, P80cdc25, by a Human Protein-tyrosine Phosphatase

Overview
Journal Science
Specialty Science
Date 1990 Dec 14
PMID 1703321
Citations 66
Authors
Affiliations
Soon will be listed here.
Abstract

The onset of M phase requires the activation of the pp34 protein kinase in all eukaryotes thus far examined. In Schizosaccharomyces pombe, pp34 is phosphorylated on Tyr15, and dephosphorylation of this residue regulates the initiation of mitosis. In this study, it is shown that dephosphorylation of Tyr15 triggered activation of the pp34-cyclin complex from fission yeast, that a human protein-tyrosine phosphatase can catalyze this event both in vitro and in vivo, and that activation of fission yeast pp34 does not require threonine dephosphorylation. The complementary DNA that encoded the tyrosine phosphatase replaced the mitotic activator p80cdc25, closely associating the cdc25(+)-activating pathway with tyrosine dephosphorylation of pp34.

Citing Articles

Identification of mutants with increased variation in cell size at onset of mitosis in fission yeast.

Scotchman E, Kume K, Navarro F, Nurse P J Cell Sci. 2021; 134(3).

PMID: 33419777 PMC: 7888708. DOI: 10.1242/jcs.251769.


CDK Regulation of Meiosis: Lessons from and .

Mackenzie A, Lacefield S Genes (Basel). 2020; 11(7).

PMID: 32610611 PMC: 7397238. DOI: 10.3390/genes11070723.


Apical Constriction Reversal upon Mitotic Entry Underlies Different Morphogenetic Outcomes of Cell Division.

Ko C, Kalakuntla P, Martin A Mol Biol Cell. 2020; 31(16):1663-1674.

PMID: 32129704 PMC: 7521848. DOI: 10.1091/mbc.E19-12-0673.


Prolonged cyclin-dependent kinase inhibition results in septin perturbations during return to growth and mitosis.

Gihana G, Musser T, Thompson O, Lacefield S J Cell Biol. 2018; 217(7):2429-2443.

PMID: 29743192 PMC: 6028541. DOI: 10.1083/jcb.201708153.


Molecular mechanisms of OLIG2 transcription factor in brain cancer.

Tsigelny I, Kouznetsova V, Lian N, Kesari S Oncotarget. 2016; 7(33):53074-53101.

PMID: 27447975 PMC: 5288170. DOI: 10.18632/oncotarget.10628.